Johnson & Johnson flies from San Francisco to Pennsylvania after $1B Firefly Bio acquisition

Johnson & Johnson's Gulfstream G650ER (N400J) departed Buchanan Field in California on the afternoon of June 10, landing four hours and forty-four minutes later near Harrisburg, Pennsylvania. The flight came just two days after Johnson & Johnson announced it would acquire Firefly Bio, a South San Francisco-based biotech, for $1 billion in cash, as reported by the company's investor relations site [investor.jnj.com](https://www.investor.jnj.com/investor-news/news-details/2026/Johnson--Johnson-to-Acquire-Firefly-Bio-Inc--to-Expand-Oncology-Pipeline-with-Novel-Degrader-Antibody-Conjugate-platform/default.aspx).

The acquisition adds Firefly's Firelink degrader antibody conjugate platform, which targets KRAS-driven tumors—an area Johnson & Johnson has called an 'undruggable' target with high unmet need. While the destination near Harrisburg is not Johnson & Johnson's New Brunswick headquarters, the region hosts several of the company's manufacturing and R&D facilities, making a site visit or integration planning likely. Per FierceBiotech, the deal positions Johnson & Johnson in the emerging DAC space, a hybrid of antibody-drug conjugates and targeted protein degraders [fiercebiotech.com](https://www.fiercebiotech.com/biotech/jj-makes-1b-upfront-bet-emerging-dac-space-netting-firefly-bio).

Recent flights for N400J show a pattern of global travel—including stops in Tokyo and Anchorage in late May—and a trip to Ireland earlier in the week. This latest cross-country jaunt suggests the C-suite is in motion as the company digests its largest oncology bet of 2026.